Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | M6PR | P20645 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 4/20 | 0.40 |
| ▸ | SI | P14410 | 4/20 | 0.40 |
| ▸ | G6PD | P11413 | 2/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070982 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15215703 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15121661 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL2505909 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15273797 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL2233716 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL24605082 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL1832193 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15273793 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL13509342 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144317-A1 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | INSTITUT PASTEUR (FR) | 2011-06-16 | — | — | US | claimed |
| EP-2100966-A1 | Mutants of glycoside hydrolases and uses thereof for synthesizing complex oligosaccharides and disaccharide intermediates | Institut Pasteur (FR) | 2009-09-16 | — | — | EP | claimed |
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20240182507-A1 | BIARYL AMIDES WITH MODIFIED SUGAR GROUPS FOR TREATMENT OF DISEASES ASSOCIATED WITH HEAT SHOCK PROTEIN PATHWAY | REATA PHARMACEUTICALS, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | REATA PHARMACEUTICALS, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | REATA PHARMACEUTICALS, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | REATA PHARMACEUTICALS, INC (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023066885-A1 | SAPONIN PRODUCTION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-04-27 | — | — | WO | disclosed |
| US-20200281956-A1 | ANTIBACTERIAL COMPOSITION CONTAINING A DEOXYHEXOSE ALKYL MONOACETAL OR MONOETHER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-09-10 | — | — | US | disclosed |
| US-20170260210-A1 | METHOD FOR PREPARING MARMYCIN A AND ANALOGUES THEREOF, AND ALSO USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-09-14 | — | — | US | disclosed |
| US-20170260210-A1 | METHOD FOR PREPARING MARMYCIN A AND ANALOGUES THEREOF, AND ALSO USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-09-14 | — | — | US | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| EP-0720616-A1 | NOVEL DEOXY AND OXYGEN-SUBSTITUTED SUGAR-CONTAINING 14-AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-10 | — | — | EP | disclosed |
| EP-0510902-B1 | Immunoassay for detecting group B streptococcus | CA NAT RESEARCH COUNCIL (CA) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| WO-1995008558-A1 | NOVEL DEOXY AND OXYGEN-SUBSTITUTED SUGAR-CONTAINING 14-AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-30 | — | — | WO | disclosed |
| US-5225331-A | Monorhamnosyl and trirhamnosyl epitopes, selectivity | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1993-07-06 | — | — | US | disclosed |
| WO-1992019969-A1 | IMMUNOASSAY FOR DETECTING GROUP B STREPTOCOCCUS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1992-11-12 | — | — | WO | disclosed |
| EP-0510902-A1 | Immunoassay for detecting group B streptococcus | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1992-10-28 | — | — | EP | disclosed |
| US-4672057-A | ANTITUMOR AGENTS; TAA ANTIBIOTICS | FARMITALIA CARLO ERBA S.P.A. (IT) | 1987-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144317-A1 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | GBA3, DDOST, UGCG | M6PR 128/4885MGAM 16/4885SI 219/4885 |
| US-20200281956-A1 | ANTIBACTERIAL COMPOSITION CONTAINING A DEOXYHEXOSE ALKYL MONOACETAL OR MONOETHER | DPM1, GNE, DERA | M6PR 270/4885MGAM 11/4885SI 378/4885 |
| US-20240182507-A1 | BIARYL AMIDES WITH MODIFIED SUGAR GROUPS FOR TREATMENT OF DISEASES ASSOCIATED WITH HEAT SHOCK PROTEIN PATHWAY | HSPA2, HSPA1A, HSP90AB1 | M6PR 4288/4885MGAM 143/4885SI 1114/4885 |
| US-20170260210-A1 | METHOD FOR PREPARING MARMYCIN A AND ANALOGUES THEREOF, AND ALSO USES THEREOF | MFN2, TMEM70, UQCRC2 | M6PR 1747/4885MGAM 1543/4885SI 3170/4885 |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | HSPA2, HSP90AB2P, HSF1 | M6PR 4212/4885MGAM 199/4885SI 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.